header image

Mexico City Plant, Mexico


Five years after Octapharma entered the Mexican market, the Group decided to start manufacturing octanate®  and albumin in the country using plasma Fraction V supplied by Octapharma's European plants. Accordingly, a production site was built between 1999 and 2001 in order to perform the second viral inactivation (heat treatment) and incubation steps.


In 2003 Octapharma purchased a plant from Probifa SA, which produced a limited range of plasma derivatives, mainly albumin, for the local market. Located in the northwest of Mexico City, the plant was converted to perform the second viral inactivation and incubation steps to also produce octanate® and albumin from Fraction V supplied by Octapharma's European plants. The products are analyzed and released for the Mexican market. Octapharma S.A de C.V. is today the only producer of blood derivatives in Mexico.


In 2009 the plasma storage area was completely renovated. The plant now has a total storage capacity of 20,000 litres of frozen plasma for a self-sufficiency project already ongoing for Mexico, thus providing plasma derivatives for the country from its own plasma.


The plant currently covers an area of approximately 5,000 m². Octapharma will invest up to €14 million over the next 3-5 years to implement a basic fractionation unit with a total capacity of up to 300,000 litres of plasma per year. The current purification area will also upgraded and extended to produce octanate® and octagam® and new analytical laboratories and administration units will be built, resulting in a state-of-the-art facility in line with the corporate Octapharma standard.


Products are analysed and released for the Mexican market by the Quality Control Department and Qualified Person at Octapharma S.A de C.V.


On-site units
Fractionation/purification; pharmaceutical production; labelling, packaging and storage facilities; Quality Control laboratories; administrative units


On-site subsidiaries
Octapharma S.A. de C.V. Mexico

Products manufactured

albunormTM, octanate®




Annual plasma fractionation capacity

to be established


“The personal involvement of Octapharma employees with patients, parents, doctors, and regulatory officials have contributed to the development of a strong relationship based on trust.”